Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04902872 · ClinicalTrials.gov registry record · Phase 1
Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
A Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Cybrexa Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 130
- Enrollment target
- 4
- Study locations
NCT04902872: Active Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, sponsored by Cybrexa Therapeutics.
NCT04902872 is a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Cybrexa Therapeutics. The registered enrollment target is 130 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04902872, a Phase 1 study of Breast Cancer and Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Cybrexa Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 130 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
Primary Outcome
NCI CTCAE v5.0
Conditions Studied
Interventions
- DRUG CBX-12
Study Locations (4)
Texas
- NEXT Oncology - Austin
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Connecticut
- Yale Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2021-05-03 |
| Est. Completion | 2025-06 |
| Phase | Phase 1 |
What the registry record for NCT04902872 still lists
NCT04902872 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 10 conditions, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which CBX-12 is the first listed.
NCT04902872 reports a single indexed study location in Texas, Connecticut.
Frequently Asked Questions
What is clinical trial NCT04902872 about?
NCT04902872 is a clinical study titled "Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors". This is a first-in-human, Phase 1/2 open-label, multicenter, dose-escalation, safety, pharmacokinetics (PK), and biomarker study of CBX-12 in subjects with advanced or metastatic refractory solid tumors.
What is the current status of trial NCT04902872?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 130 participants. The study started on 2021-05-03. Estimated completion is 2025-06.
What conditions does trial NCT04902872 study?
This clinical trial studies the following conditions: Breast Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer, Gastric Cancer, Solid Tumor, Adult.
What interventions are being tested in trial NCT04902872?
The interventions under investigation include: CBX-12 (DRUG).
Who is sponsoring clinical trial NCT04902872?
This trial is sponsored by Cybrexa Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04902872 being conducted?
This trial has 4 study locations across Connecticut, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04902872's enrollment target sits among peer trials
130 489th of 1224 higher than 730 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI